Regional Content Customized for Australia

This section contains resources customized for the Australian healthcare professional.

COVID-19 Vaccine Recommendations for IO Patients

In the following videos, Professor Grant McArthur, Executive Director of the Victorian Comprehensive Cancer Center and Co-Chair of the Victorian COVID-19 Cancer Network, discusses the use of COVID-19 vaccines in patients with cancer, particularly in those receiving immune checkpoint inhibitors (ICIs). The content is customised to the Australian region. This content was recorded on October 5, 2021 and reflects the status of vaccine approvals as of that date. For an updated list of the currently available vaccines approved in Australia, please click here https://covid19.trackvaccines.org/country/australia/

 

Review of available COVID-19 vaccines

 

Timing of vaccines with different therapies (eg, recipients of stem cell transplantation/CAR T-cells)

 

COVID-19 vaccines and ICIs (sequencing, monitoring, and side effects)

 

Addressing frequently asked questions and myths about COVID-19 vaccines

 

Effective patient educational techniques and strategies to address vaccine hesitancy

 

What to look for in the future regarding COVID-19 vaccines in patients with cancer

Stage III Decision-Support Materials

Updated Stage III Decision Support Tool

The Decision-Support Tool has been updated with information you need to know about outcomes for Stage III melanoma, long-term data for adjuvant therapies, and additional resources, including content specific for caregivers.

Developed in collaboration with the Melanoma & Skin Cancer Advocacy Network.

New Stage III Companion Piece

Want to learn how to use the Stage III Decision-Support Tool? Peruse frequently asked questions about Stage III melanoma and learn how to use the support tool to guide your decision making.

Developed in collaboration with Melanoma & Skin Cancer Advocacy Network.

Optimising Care During the COVID-19 Pandemic

In the series of videos below, Suzanne Bartlett, RN Grad Cert(Can& Pall), MAdvNursPrac(NPRAC), of Ballarat Regional Integrated Cancer Centre, shares perspectives and tips for optimising care during these challenging times. Note that the phase of lock down discussed in these videos was specific to the time of the recording. In addition, the extended dosing interval discussed for pembrolizumab was limited to the melanoma indication at the time of the recording.

Optimising Telemedicine

Use of Extended Dosing Intervals for Immunotherapy

Changes in Infusion Practices

Minimising the Impact on Clinical Trials

Care Step Pathways

This section provides stand-alone Care Step Pathways (CSPs) that have been customized for the Australian audience. We wish to thank Suzanne Bartlett, RN, Grad Cert(Can&Pall), MAdvNursPrac(NPRAC), of the Ballarat Regional Integrated Cancer Centre for thoughtful review of these materials.


List of CSPs

For Immunotherapy (Checkpoint Inhibitors):
Ipilimumab
Nivolumab
Pembrolizumab
Nivolumab/Ipilimumab

For Intralesional Therapy:
Talimogene laherparepvec; T-VEC

Patient Resources/Action Plans

This section contains the customizable action plans for patients with different tumor types that have been customized for the Australian  audience. We wish to thank Tamara Dawson, of the Melanoma & Skin Cancer Advocacy Network, for her helpful review of these materials.

Talimogene laherparepvec; T-VEC

Pembrolizumab

Nivolumab

Nivolumab/Ipilimumab

Ipilimumab